Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities
National Institute of Allergy and Infectious Diseases (NIAID)
The purpose of this study is to see whether metformin alone, rosiglitazone alone, or
metformin and rosiglitazone together will lower insulin levels in the blood and decrease fat
in the abdomen or other parts of the body.
Studies have shown that certain anti-HIV medications can cause a number of side effects,
including high blood sugar (resulting from the body's failure to use insulin), high insulin,
and excess fat build-up in the abdominal area. These side effects are known to increase the
risk of heart disease. Metformin and rosiglitazone are 2 drugs that have been shown to lower
insulin resistance and lessen abdominal fat in patients who are not HIV-infected. This study
will investigate the use of these drugs in HIV-infected patients.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.